Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, l-NAME and l-arginine worsen
- 88 Downloads
Stable gastric pentadecapeptide BPC 157, administered before a high-dose magnesium injection in rats, might be a useful peptide therapy against magnesium toxicity and the magnesium-induced effect on cell depolarization. Moreover, this might be an NO-system-related effect. Previously, BPC 157 counteracts paralysis, arrhythmias and hyperkalaemia, extreme muscle weakness; parasympathetic and neuromuscular blockade; injured muscle healing and interacts with the NOS-blocker and NOS-substrate effects.
Assessment included magnesium sulfate (560 mg/kg intraperitoneally)-induced muscle weakness, muscle and brain lesions, hypermagnesemia, hyperkalaemia, increased serum enzyme values assessed in rats during and at the end of a 30-min period and medication (given intraperitoneally/kg at 15 min before magnesium) [BPC 157 (10 µg, 10 ng), l-NAME (5 mg), l-arginine (100 mg), alone and/or together]. In HEK293 cells, the increasing magnesium concentration from 1 to 5 mM could depolarize the cells at 1.75 ± 0.44 mV.
l-NAME + magnesium-rats and l-arginine + magnesium-rats exhibited worsened severe muscle weakness and lesions, brain lesions, hypermagnesemia and serum enzymes values, with emerging hyperkalaemia. However, l-NAME + l-arginine + magnesium-rats exhibited all control values and normokalaemia. BPC 157 abrogated hypermagnesemia and counteracted all of the magnesium-induced disturbances (including those aggravated by l-NAME or l-arginine). Thus, cell depolarization due to increasing magnesium concentration was inhibited in the presence of BPC 157 (1 µM) in vitro.
BPC 157 likely counteracts the initial event leading to hypermagnesemia and the life-threatening actions after a magnesium overdose. In contrast, a worsened clinical course, higher hypermagnesemia, and emerging hyperkalaemia might cause both l-NAME and l-arginine to affect the same events adversely. These events were also opposed by BPC 157.
KeywordsBPC 157 l-Arginine l-NAME Magnesium Rats
This research was supported by the Ministry of Science, Education and Sports, Republic of Croatia (Grant Number 108-1083570-3635).
Compliance with ethical standards
Conflict of interest
The authors indicate no potential conflicts of interest.
- Bowman WC (1983) Peripherally acting muscle relaxants. In: Parnham MJ, Bruinvels J (eds) Discoveries in pharmacology, volume I: psycho- and neuro-pharmacology. Elsevier Science Publishers BV, Amsterdam, pp 106–159Google Scholar
- Ilic S, Brcic I, Mester M et al (2009) Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol 60(Suppl 7):107–114PubMedGoogle Scholar
- Lojo N, Rasic Z, Zenko Sever A et al (2016) Effects of diclofenac, l-NAME, l-Arginine, and pentadecapeptide BPC 157 on gastrointestinal, liver, and brain lesions, failed anastomosis, and intestinal adaptation deterioration in 24 hour-short-bowel rats. PLoS One 11(9):e0162590CrossRefPubMedPubMedCentralGoogle Scholar
- Sikiric P, Seiwerth S, Rucman R et al (2016) Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications. Curr Neuropharmacol [Epub ahead of print]Google Scholar